Clinical trials: Low Risk Prostate Cancer, open to volunteers
Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume
Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer
*Rationale : Active surveillance of prostate cancer helps to avoid the morbidity associated with curative radical prostatectomy /radiotherapy in patients with early stage disease.
- Conditions
- Macroscopic Tumor Visualized at MRI, Tumor Size Allowing Partial Prostate Treatment Volume, CAPRA SCORE ≤5
- Trial name
- TOPPGUN-RS (NCT07152067)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Belgium
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Prostate Carcinoma, Erectile Function
Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers
This prospective randomized controlled trial (RCT) is designed to provide high level evidence on the efficacy of Low-intensity Extracorporeal Shock Wave Therapy (Li-ESWT) in the treatment of post-Robot-Assisted (RA) Radical…
- Conditions
- Prostate Carcinoma, Erectile Function, Genito Urinary Cancer
- Trial name
- RCT_LiESWT (NCT06717711)
- Testing
- Low-intensity Extracorporeal Shock Wave Therapy (LiESWT), PDE5 inhibitor (tadalafil)
- Where
- 2 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Regina Elena Cancer Institute
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abiraterone acetate and prednisone, for the treatment of hormone-sensitive prostate cancer has spread to a limited…
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Trial name
- SPARKLE (NCT07650240)
- Testing
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Brachytherapy
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease.
- Conditions
- Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-N (NCT07426094)
- Testing
- Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells.
- Trial name
- NCT06347705
- Testing
- 2141-V11 Antibody
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
- Trial name
- FOKAL-BT (NCT02391051)
- Testing
- HDR-Brachytherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Prostate Cancer, Cancer of the Prostate
Low-Count Quantitative SPECT for Men Treated With Radium-223
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues.
- Trial name
- NCT07221825
- Testing
- Low-count quantitative single-photon emission computed tomography imaging
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Metastatic Breast Cancer, Metastatic Prostate Cancer
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performance of the DOTA-STR-17126 theranostic pair in patients with advanced or metastatic breast or prostate cancer.
- Conditions
- Metastatic Breast Cancer, Metastatic Prostate Cancer, GRPR-Targeted Molecular Imaging, Theranostic Radiopharmaceuticals
- Trial name
- DOTA-STR-17126 (NCT07608848)
- Testing
- [177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Integrated Haematology and Oncology Network
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Post Prostatectomy)
Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial
The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer (Post Prostatectomy), Prostate Cancer Surgery, Prostate Cancers
- Trial name
- NCT06915909
- Testing
- surgery
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- East and North Hertfordshire NHS Trust
Localized Prostate Cancer, Low Risk Prostate Cancer
The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer.
- Conditions
- Localized Prostate Cancer, Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
- Trial name
- PRECISION (NCT06117059)
- Testing
- 3 fractions of prostate SBRT
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Lothian
Prostate Cancer Metastatic Disease
Efficacy and Tolerability of Low-Dose Enzalutamide in Prostate Cancer
Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer-related mortality in males.
- Trial name
- LODE (NCT06718647)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Monica Boitano
Prostate Cancer
Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM)
This study compares the effectiveness of low-field MRI (0.55T) with high-field MRI (3T) in prostate cancer screening and image quality.
- Trial name
- Low-PRISM (NCT06482489)
- Testing
- Siemens Magnetom Free.Max 0.55T (Siemens Healthineers, Erlangen, Germany).
- Where
- Switzerland
- Volunteers
- 74 people
- Sponsor
- University of Lausanne Hospitals
PROSTATE CANCER
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer
The goal of this clinical trial is to compare two dose schedules of stereotactic radiation therapy in patients with localized prostate cancer.
- Trial name
- SABR-Dual (NCT06027892)
- Testing
- Two-fraction stereotactic radiotherapy, Five-fraction stereotactic radiotherapy
- Where
- Israel
- Volunteers
- 562 people
- Sponsor
- Rabin Medical Center
Prostatic Neoplasms
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
The goal of this clinical trial is to learn if a low to moderate load power training program is feasible and effective for improving fitness and quality of life of people with prostate cancer under androgen suppression therapy…
- Trial name
- NCT07572760
- Testing
- Power training group
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- University of Alicante
Prostate Cancer
Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy
The TEMPOS-GEniToUrinary Group (GETUG) study is a multicenter, medico-economic study comparing brachytherapy to SBRT in low and intermediate risk prostate cancer, particularly focused on the issue of erectile dysfunction.
- Trial name
- TEMPOS (NCT03830788)
- Testing
- Radiation by brachytherapy, Radiation by SBRT
- Where
- 20 sites in France
- Volunteers
- 240 people
- Sponsor
- Center Eugene Marquis
Prostate Carcinoma, Prostate Neoplasm
Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.
The AirSeal platform has been evaluated in urological surgeries, mainly in cases of malignant diseases 5,6. However, there is still a lack of data demonstrating the possible benefits of its use, which justifies the conduct of…
- Conditions
- Prostate Carcinoma, Prostate Neoplasm, Pain Intensity Assessment, Quality of Life (QOL)
- Trial name
- ARCO2 (NCT06784986)
- Testing
- The Conventional Insufflation System, AirSeal® System
- Where
- 2 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Brazilian Institute of Robotic Surgery
Prostatectomy
A Comparison of Radical Prostatectomy and Precision Prostatectomy in Low- and Intermediate-risk Prostate Cancers.
Prostate cancer (PCa) management for low- and intermediate-risk patients often involves radical prostatectomy (RP), which achieves oncologic control but is associated with significant functional impairments, such as erectile…
- Trial name
- NCT07348367
- Testing
- Radical Prostatectomy, Precision Prostatectomy
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Henry Ford Health System
Prostate Cancer, Kidney Cancer
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving cancer trial enrollment of patients treated in…
- Trial name
- NCT06138067
- Testing
- High intensity approach, Low intensity approach
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Adenocarcinoma
Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer
Prostate cancer is a common malignancy in men, with rising incidence worldwide. Current clinical risk assessment tools-including PSA, Gleason score/ISUP grade, pathological stage, margin status, perineural invasion, and…
- Trial name
- NCT07818421
- Testing
- Validate spatial localization of candidate microbial signals via 16S rRNA ISH, FISH, immunofluorescence, IHC, and spatial omics.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Anhui Medical University
Metastatic Prostate Cancer
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer.
- Trial name
- NCT07224009
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas